On March 25, 2022, Grand Industrial Holding Co.Ltd(000626) released the annual report for 2021, and the company achieved an operating revenue of 81.562 billion yuan, a year-on-year increase of 38.14%; The net profit attributable to the shareholders of the listed company was 222 million yuan, a year-on-year increase of 296.25%.
Yuanda pharmaceutical said that during the reporting period, while vigorously developing bulk commodity trade, the company attached great importance to the R & D and innovation of biological pesticides, firmly laid out the development direction of high-tech agriculture, quickly combined trade with industry and high technology, and was committed to becoming a large-scale trade industry integration high-tech enterprise integrating trade with industry and high technology.
In 2021, the company continued to make steady progress in commodity channel services, price management and international business, optimized and refined the risk management system, and achieved good business performance thanks to the overall rise in commodity prices.
In addition, Grand Industrial Holding Co.Ltd(000626) officially launched the industrialization process of ecological agriculture and made a strategic layout towards high-tech agriculture and biopesticides. It successively established the "modern agricultural research and development center" with the Plant Protection Research Institute of the Chinese Academy of Agricultural Sciences, and acquired Kaili biological, a biopesticide high-tech enterprise with the exclusive patent of mesobiotic technical medicine, Signed a framework agreement to acquire Shaanxi mccolow, a new "little giant" enterprise specializing in biological pesticides; In March 2022, Grand Industrial Holding Co.Ltd(000626) exclusively transferred a series of scientific and technological achievements such as pesticide registration certificate and relevant invention patents of oryzanol technical drugs and preparations independently owned by Northeast Agricultural University.
Among them, in 2021, Kaili biology achieved an operating revenue of 141 million yuan, a year-on-year increase of 21.16%; The net profit was 423146 million yuan, a year-on-year increase of 38.81%, exceeding the promised performance.
